Moderna's remarkable 2026 stock rally came to a crashing halt on Thursday, October 22, as shares of the biotech company fell as much as 26% during the session before recovering part of the loss to close at $202.63, down 17.6% — the steepest one-day closing decline since August — wiping out more than $17 billion in market value. At the session low, the paper loss had reached about $24 billion. The trigger was leaked late-stage trial data for intismeran, the personalized mRNA cancer vaccine Moderna is developing in partnership with Merck, that fell short of the market's sky-high expectations. Here is the twist that has Wall Street talking: the data itself was solid. Analysts rushed to call it "great" and "encouraging." The selloff, they say, was a textbook case of investors selling the news.

The episode has been trending across financial news coverage this hour, drawing attention not just for the scale of the market move but for what it reveals about one of the most ambitious bets in modern medicine — a vaccine built for each patient's own tumor.

What happened to Moderna shares

Moderna (NASDAQ: MRNA) shares fell as much as 26% during Thursday's session before recovering to close at $202.63, down $43.18, or 17.6%. At the close, the sell-off had erased more than $17 billion from the drugmaker's market value — about $24 billion at the session low — and abruptly halted a massive rally that had lifted the stock more than 500% this year. Merck (NYSE: MRK), Moderna's partner on the vaccine, also fell, recovering part of its losses by the close.

The speed of the reversal is what startled the market. In August, Moderna shares more than doubled after the company announced that its late-stage trial had met its primary endpoint — news that reignited enthusiasm for a company still proving it can thrive beyond its COVID-19 vaccine franchise. The reversal echoed other sharp post-earnings swings across big-cap stocks this month, but few have matched its violence. By Thursday, that euphoria had collapsed in a single trading day.

The trial data behind the selloff

The leaked data came from the Phase 3 INTerpath-001 trial, a late-stage study testing Moderna and Merck's personalized cancer vaccine, intismeran autogene, in combination with Merck's blockbuster immunotherapy Keytruda (pembrolizumab). The trial enrolled more than 1,100 patients with resected high-risk melanoma — people whose tumors had been surgically removed but who face a high risk of the cancer returning.

According to the detailed results released Thursday, intismeran combined with Keytruda reduced the risk of cancer recurrence or death by 42% compared to Keytruda alone after a median follow-up of 24.6 months. The combination also cut the risk of distant metastasis — the spread of cancer to distant organs — or death by 38% compared to Keytruda alone.

These are, by any clinical measure, strong results. Moderna had previously said that a 35% reduction would constitute a clinically significant outcome. For context, Keytruda alone had shown a 43% reduction compared with a placebo in earlier research. The problem was not the medicine — it was the market. Wall Street investors had been expecting the intismeran regimen to show anywhere from a 40% to 50% relative reduction in the risk of recurrence or death, making the 42% figure feel like a letdown after a 500% rally.

How the data leaked before ESMO

The results were not supposed to become public on Thursday. Moderna and Merck had planned to present the full data this Saturday, October 24, at the European Society for Medical Oncology (ESMO) Congress 2026, in a prestigious Presidential Symposium slot — one of the most eagerly anticipated presentations in the biotechnology sector this year.

Instead, screenshots of the findings surfaced on the website Oncology Central and circulated on social media earlier in the day. ESMO confirmed in a post on X that the embargo on the study data had been "breached," stating that as the data were now publicly available, it was releasing the abstract and lifting the embargo on the full dataset. Moderna and Merck responded by rushing out their own press release with the complete results, turning a carefully staged scientific reveal into a chaotic trading event.

The leak-driven chaos helps explain the violence of the market reaction. Investors had to digest dense clinical data in real time, without the usual presentation context, while social media amplified the most negative interpretations. It was the worst possible setting for a stock priced for perfection.

Why investors sold the news

The market's verdict was not really about 42% versus 50%. It was about valuation. After doubling in August and climbing more than 500% this year, Moderna was priced as if intismeran were a near-certain multi-billion-dollar franchise. Analysts at William Blair noted that investors may now be questioning whether the treatment will prove as effective in other cancer types — a key part of the bullish case — to justify the lofty valuation.

This is the classic "sell-the-news" dynamic: traders buy the rumor, ride the anticipation, and take profits the moment the actual news arrives, no matter how good it is. UBS analyst Michael Yee called the recurrence-free survival results "solid data" and described the pullback as an expected sell-the-news event, noting that expectations had been inflated by bullish commentary from the companies themselves. Jefferies analysts called the data "encouraging," while William Blair's Myles Minter described the trial results as "great" and concurred that the reversal appeared to be a sell-the-news reaction.

The episode is a familiar pattern in biotech investing, where stocks can trade less on clinical outcomes than on the gap between those outcomes and overheated expectations. Similar sell-the-news episodes have followed big data releases from other volatile stocks this month, and they rarely settle the underlying question of a drug's value — they just reset the price at which the market debates it.

What analysts are saying

Beneath the market panic, the professional read on the data was notably calm. UBS said the results raised its confidence in related studies of the platform. Jefferies projected that the combination, if priced near Keytruda's roughly $200,000 per patient, could reach multi-billion-dollar peak sales in melanoma alone, noting that the American Cancer Society expects about 112,000 new melanoma cases in the United States in 2026.

The more cautious voices focused on durability and breadth. Moderna's rally had been fueled by the hope that personalized mRNA vaccines could work across many cancer types; the melanoma data, however strong, is still a single indication. Whether intismeran can replicate a 40%+ risk reduction in larger, more diverse trials — and in harder-to-treat cancers — is the question that will determine whether the vaccine justifies even the post-selloff valuation.

What intismeran could mean for cancer treatment

Stepping back from the stock chart, the science remains striking. Intismeran is a personalized neoantigen therapy: after a patient's tumor is surgically removed, scientists sequence it to identify mutations unique to that cancer, then build a custom mRNA vaccine that trains the patient's immune system to recognize and attack cells carrying those mutations. Combined with Keytruda, which removes the brakes on immune cells, the approach is designed to hunt down the microscopic remnants of cancer that cause relapse.

If the melanoma results hold up through regulatory review, intismeran could become the first approved personalized mRNA cancer vaccine — a milestone the industry has chased for decades. Drug pricing and access debates, like India's recent cap on cancer drug trade margins, will shape who ultimately benefits if the vaccine is approved. That is why the trial mattered far beyond one company's share price, and why the data will be pored over when it is formally presented at ESMO on Saturday.

What happens next

The immediate focus is the full ESMO presentation on October 24, where investigators will lay out the complete dataset, including safety and subgroup details that Thursday's rushed release did not cover. After that, attention turns to Moderna's regulatory timeline, the Phase 3 follow-through, and whether the platform can extend into other cancers.

For the stock, the question is whether the sell-the-news reset creates a new entry point or marks the end of the 2026 biotech mania. The rally that doubled the shares in August was built on interim data; the full data is better characterized, and arguably more de-risked. But markets that rise 500% on hope can fall 17.6% in a single session on detail — and Thursday was a reminder that in biotech, the gap between a great drug and a great stock can be very wide indeed.

The story has dominated financial headlines worldwide in the hours since the leak, and it will likely stay in focus through the weekend's medical meeting. For patients and physicians, the headline number — a 42% reduction in recurrence or death — is the one that matters. For investors, the lesson of the day is older than the stock market itself: buy the rumor, sell the news.

Sources: Reuters, Investopedia, Wall Street Journal, Barron's, BioPharma Dive, ESMO.

The sector's promise is real, though: a personalised mRNA vaccine cut melanoma recurrence risk by 42% in a world-first trial.